Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of RDX-002 on Postprandial Triglycerides in Patients Discontinuing the Glucagon-like Peptide-1 (GLP-1) Agonists, Semaglutide or Tirzepatide, for the Treatment of Obesity
Conditions
Interventions
RDX-002
Placebo
Locations
1
United States
Nucleus Network
Saint Paul, Minnesota, United States
Start Date
September 27, 2024
Primary Completion Date
January 4, 2025
Completion Date
May 13, 2025
Last Updated
December 23, 2025
NCT07154186
NCT07063056
NCT06357299
NCT06420817
NCT04148339
NCT06230705
Lead Sponsor
Response Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions